Free tool
FAERS Monitor: Yondelis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207953 or its brand name (Yondelis, Trabectedin). Reports on generic versions are filed under their own applications.
Reports
2,350
Serious
2,142
91% of reports
Hospitalization
1,049
Death reported
464
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia251
- anaemia214
- nausea206
- thrombocytopenia202
- febrile neutropenia163
- pancytopenia161
- off label use154
- vomiting151
- disease progression139
- rhabdomyolysis132
- alanine aminotransferase increased125
- asthenia107
- aspartate aminotransferase increased106
- drug ineffective106
- pyrexia103
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 12 |
| 2011 | 44 |
| 2012 | 27 |
| 2013 | 28 |
| 2014 | 35 |
| 2015 | 82 |
| 2016 | 344 |
| 2017 | 254 |
| 2018 | 266 |
| 2019 | 213 |
| 2020 | 151 |
| 2021 | 132 |
| 2022 | 157 |
| 2023 | 153 |
| 2024 | 173 |
| 2025 | 127 |
| 2026 | 133 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,809 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rhabdomyolysisSignal | 132 | 28.4 | 24.1 | 3,461 |
| pancytopeniaSignal | 161 | 25.9 | 22.3 | 3,821 |
| febrile neutropeniaSignal | 163 | 22.0 | 19.0 | 3,256 |
| alanine aminotransferase increasedSignal | 125 | 18.3 | 15.4 | 2,024 |
| aspartate aminotransferase increasedSignal | 106 | 17.9 | 14.9 | 1,675 |
| neutropeniaSignal | 251 | 16.6 | 14.7 | 3,669 |
| thrombocytopeniaSignal | 202 | 16.2 | 14.2 | 2,875 |
| disease progressionSignal | 139 | 10.5 | 9.0 | 1,194 |
| anaemiaSignal | 214 | 10.1 | 8.8 | 1,749 |
| vomitingSignal | 151 | 2.9 | 2.5 | 187 |
| pyrexiaSignal | 103 | 2.7 | 2.2 | 107 |
| astheniaSignal | 107 | 2.5 | 2.1 | 101 |
| nauseaSignal | 206 | 2.3 | 2.0 | 161 |
| off label use | 154 | 1.6 | 1.4 | 33 |
| drug ineffective | 106 | 0.7 | 0.6 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.